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Calciphylaxis is usually non-ulcerating: Risk factors, outcome usually been considered to be the hallmark sign of the
and therapy. condition. However, we have previously described a se-
Background. Calciphylaxis, historically considered rare, seems ries of patients presenting with dense, non-ulceratingto be increasing in frequency. In our single center, 36 new cases
plaques in the calves [6] and this appears to be the mosthave accumulated in seven years. The majority of these cases
common mode of presentation in our center. In the pastwere non-ulcerating, which we believe to be early disease, in
contradistinction to the vast majority of published cases that seven years, we have encountered 36 patients with the
presented with ulcers. condition, only 20% presenting with ulcers. Those with
Methods. Prospective data were collected on all patients with ulcers have a very high mortality rate [7]. Others havecalciphylaxis. As well, a case control study, with two controls
also noted an increasing frequency of the disease [8].per patient, was performed on patients presenting with non-
The subcutaneous calcium deposition can usually be de-ulcerating plaques.
Results. The incidence of calciphylaxis in dialysis patients in- tected by bone scan [6, 9].
creased with a rate of 4.5/100 patient-years in the past three Various putative risk factors have been reported. High
years. Eighty percent of cases presented with non-ulcerating
serum Ca  P product has been implicated by somesubcutaneous plaques in the calves, easily confused with cellu-
[10, 11] but not others [4, 12]. Female gender seems tolitis. In those patients presenting with plaques only, the mortal-
ity rate was 33% at six months. Once ulceration develops, the be a risk factor [4, 13, 14]. The parathyroid hormone
mortality rate increased to above 80%. Bone scan was positive (PTH) level may [15] or may not be [4] a risk factor.
in 97% of patients. Steroid therapy appeared to be beneficial Oral CaCO3 dose has been reported as increasing thein some patients. Peritoneal dialysis, female sex and diabetes
likelihood of the disease [4, 9] but this was not the casewere risk factors. In the case control study of patients present-
in a recent study [11]. Part of the above discrepanciesing with plaques only, serum phosphate (OR 2.6; 95% CI 1.05
to 6.45, P  0.038) and Ca  P product (OR 1.46; 95% CI lie in the relatively small numbers of patients with the
1.02 to 20, P 0.038) predicted the disease, as did being on cal- disease in many of these studies.
cium salts vitamin D (OR 4.05; 95% CI 1.14 to 14.5, P 0.03). This study details our entire experience of calciphy-Conclusions. Calciphylaxis is no longer rare. It is usually non-
laxis in one center over seven years, and describes the roleulcerating and can be diagnosed clinically in all patients. These
of various diagnostic tests and patient outcomes. A casepatients have a high mortality, especially once ulceration oc-
curs. Calcium salts plus vitamin D, as well as serum Ca  P control study was performed on these patients, but ex-
product and high serum P increase the chance of the diseases. cluded patients presenting with ulcers on the basis that
Therefore, the disease may be preventable. Steroids may be of ulceration probably represents later disease that there-benefit to some patients.
fore cannot be matched for time of onset. This decision
was based on two observations. Asymptomatic plaques
are often picked up on routine physical examinationCalciphylaxis, historically considered rare, is often a
in our clinics, and plaques often subsequently developfatal complication of end-stage renal disease [1–3]. It
into ulcers. Therefore, many patients with ulcerationoccurs in both peritoneal and hemodialysis patients and
may have had non-ulcerating disease for a significantcan occasionally occur pre-dialysis [4, 5]. Ulceration has
time prior to diagnosis.
Key words: hyperphosphatemia, calcium salts, dialysis, end-stage renal METHODS
disease, kidney calciphylaxis, phosphate-lowering therapy.
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peritoneal dialysis and 160 hemodialysis patients. In the able eschar. Other patients presented with multiple small
(1 to 3 cm) lesions on legs, lower abdominal wall andinitial case control study of 8 patients, controls were
matched only for duration of dialysis [4]. However, be- arms (Fig. 1).
The condition was far more common in females (P cause female sex and peritoneal dialysis were risk factors
for the disease in that study, subsequent controls, two 0.02), peritoneal dialysis (PD) patients (P  0.001) and
diabetics (P  0.02) than the dialysis population at riskper patient, have been controlled for dialysis modality,
duration of dialysis and sex. Control patients must have (Table 1). Age and duration of dialysis were not different
in cases compared with the dialysis population. Two pa-started dialysis within three months of the test case start-
ing dialysis. tients were pre-dialysis.
Hemodialysis patients were usually dialyzed against
Investigations1.6 mmol/L Ca bath. Kt/V was greater than 1.1. Perito-
neal dialysis patients were either on 4 to 5 cycles per The white blood cell (WBC) count was elevated in
some patients (15%). The bone scan showed abnormalday (75%) or cycler dialysis. The peritoneal dialysate
Ca has been 2.5 mEq/L since 1996. uptake in 97% of patients. This uptake was almost always
subcutaneous and in the clinically apparent diseased
Investigations areas, but in one patient the distribution seemed to be
at a deeper level. However, in two cases with deep ulcer-Serum calcium, phosphate and PTH were measured
by the usual laboratory methods; the upper limit of PTH ation affecting more than 50% of the surface area of the
legs below the knee, no uptake was found in the legsin our laboratory is 66 ng/L. Bone scan was performed
using 99mTc-MDP. Records of calcium salt and vitamin D but was marked in the lungs (Fig. 2). Only one patient
had a clearly negative scan (on 2 occasions) in spite of(calcitriol) ingestion were obtained by chart review.
a positive x-ray and biopsy. X-ray films of the legs were
Statistics normal in 29% of patients with confirmed disease (Table
2). The x-ray patterns varied from a diffuse, fine reticularStatistics were performed on the cases and their paired
controls for all data using multivariate conditional logis- pattern to a very coarse reticulo-nodular appearance
(Fig. 3). Often vessel calcification was very prominenttic regression for matched case-controls using the SAS
(6.12) program (SAS, Cary, NC, USA). Data are ex- and included the small hand vessels.
pressed as mean  SD where applicable.
Biopsies
The diagnosis was confirmed in all four subjects (3
RESULTS
with plaques only, 1 with extensive ulceration) who were
Incidence biopsied. However, in one patient the first two biopsies
were negative; only the third biopsy gave a definite diag-Since our first case seven years ago, a total of 36 pa-
tients have presented with clinical features of calciphy- nosis. This patient had extensive ulceration. Two non-
ulcerated patients developed extensive ulceration nearlaxis, and 79% of these cases have appeared in the past
40 months. This gives a frequency of approximately 4% the biopsy site within a few weeks.
of our PD population/year.
Natural history and therapy
Clinical features Thirty-three percent of the patients presenting with
plaques-only progressed to ulceration with an extremelyOn presentation, 80% of patients were diagnosed with
subcutaneous indurated plaques in the legs. These plaques high mortality rate (89%). The overall mortality rate
(all patients) at 6 and 12 months was 39 and 45%, respec-varied from a couple of centimeters to involving most
of the calf (Fig. 1). The most common site of initial tively, 33% if presenting with plaques only, and 67%
when presenting with ulcers (Table 3). Ulcers at anyinvolvement was 2 to 5 cm above the Achilles tendon.
It is important to note that the plaque-only presentation time increased the mortality rate to 80%; all of these
deaths were related to calciphylaxis. No ulcers at anymay be indistinguishable from cellulitis (that is, tender,
red, and warm). However, with experience, it becomes time conferred a good outlook with zero mortality at
six months. Calciphylaxis related causes of death in-easy to feel the plaques. In almost all cases, the plaques
were tender. When patients presented with ulcers, they cluded sepsis, weight loss or malnutrition (often related
to large doses parenteral analgesia), and discontinuationwere usually very painful, often necessitating strong anal-
gesics. The condition was almost always bilateral. of dialysis.
For those who presented without ulceration; steroidThe ulcers in those patients who presented with ulcer-
ation alone (17%) or ulceration plus plaque (3%) with therapy (prednisone 30 to 50 mg p.o. o.d. 3 to 8 weeks)
was administered to one half of the patients. In the earlyusually large confluent ulcers on the legs were usually
located below the knees and most often with consider- years we did not use this therapy but now use it regularly
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Fig. 1. Patterns of calciphylaxis. (A) Classical presentation with calf
plaques (often confluent), the borders of which are shown with arrows.
Parts of the skin are erythematous, which is easily confused with simple
cellulitis. (B) Gross ulceration (in the same patient 3 months later).
The black eschar has been surgically de´brided. (C ) Calciphylactic rash
on an arm. (D) Calciphylactic rash on abdomen with 2 to 3 cm ulcers,
with close-up view of lesions (E ).
because of our having seen many dramatic responses. (3 to 60 days), whereas in those patients not given any
specific therapy, any improvement was far more gradualOur contraindications to steroid therapy included ulcer-
ation anywhere (related to PVD or calciphylaxis) or high (2 to 8 months). Of these untreated patients, 55%
worsened and died of ulcerating disease.risk of infection. Eighty percent of the treated patients
improved (Table 4). In two of these 11 patients, the good Parathyroidectomy was performed in three patients
with PTH values greater than 4  normal. In all casesresponse lasted two to six months, but the condition
then relapsed into ulcerating disease. In the majority of an improvement or cure occurred. A tissue sample from
the calciphylactic area in an amputated leg and a piece ofresponders, an improvement or cure was often rapid
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Table 2. Diagnostic tests for calciphylaxisTable 1. Patient characteristics in 36 consecutive patients
with clinically apparent calciphylaxis
Positive Negative Equivocal Notes
Dialysis Presentation
X-ray 5 2a a Both had ve scans, 1population at risk
N  7 had ve biopsyAll cases patient-years Plaques Ulcers
Bone scan 34a 1b 1 a 2 of these pts had veN  36 N  1620 N  29 N  7
N  36 uptake in areas of
severe ulceration butAge 5415 5814 5512 5014
Female 27 (75%) 858 (53%)b 23 (79%) 5 (71%) ve in lungs
b X-ray ve, biopsy vePD 28 (78%) 923 (57%)b 23 (79%) 5 (71%)
Diabetes 24 (67%) 470 (29%)a 18 (62%) 6 (86%) Biopsy 4a a In one of these patients
N  4 first and second biopsyDialysis duration
months 2820 3015 3323 2920 were ve, the third one
vea P  0.001, bP  0.02, all cases vs. entire dialysis patient population at risk
Fig. 2. Bone scan abnormalities in calciphylaxis. (A) Classical calf calcification. (B) There is strongly positive lung calcification but negative uptake
in lower legs. At the time of the scan, both lower legs had gross ulceration from popliteal fossa to ankles. Other types are discussed in the Results
section.
a grossly atherosclerotic vessel from a non-renal patient data for one month of this treatment. PTH levels and
were analyzed by Fouriere-transformed infrared spec- coumadin administration were not different between
troscopy (Nicolet 510 P, Nicolet Instrument Corp., Madi- cases and controls.
son, WI, USA). In both, calcification was in the form of
carbonate apatite.
DISCUSSION
Risk factors Our results, to our knowledge the largest single unit
experience reported, demonstrate that calciphylaxis isIn the case control study of patients presenting with
far more common in dialysis patients than the literatureplaques-only, serum phosphate and Ca P product were
suggests. Contrary to the literature, most cases presentsignificant risk factors for calciphylaxis (univariate and
with non-ulcerating plaques, which we believe to be themultivariate; Table 5). Therapy with both Ca salts and
early form of the disease, that may respond to steroids.vitamin D three and four months prior to onset increased
Once ulceration develops, the six-month mortality ratethe likelihood of getting the disease (univariate OR 3.25;
drastically increases. Serum phosphate, Ca  P product95% CI 1.009 to 10.520; P  0.048) and multivariate
OR 4.05; 95% CI 1.14 to 14.5; P  0.031) with similar and combined therapy with calcium salts and vitamin D
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Fig. 3. Patterns of x-ray abnormalities in
calciphylaxis. (A) Diffuse reticular pattern
(with heavily calcified vessels). (B) Gross
confluent patches of calcification. Other
variants are discussed in the Results section.
Table 3. Mortality in 33 patients with calciphylaxis in relation to their clinical findings
Deaths % Deaths related to calciphylaxis
Method of presentation Number 6 months 12 months 6 months 12 months
Plaques only 27 9 (33%) 11 (41%) 89 73
Ulcers  plaques 6 4 (67%) 4 (67%) 100 100
All patients 33 13 (39%) 15 (45%) 93 93
Subsequent clinical status
Plaques→ulcers 9 8 (89%) 8 (89%) 100 100
Ulcers at any time 15 12 (80%) 12 (80%) 100 100
No ulcers at any time 18 0 3 (17%) 66
are risk factors for the disease, as well as female sex, the subcutaneous tissues but without vessel calcification,
the hallmark of calciphylaxis in humans. The experimen-diabetes and peritoneal dialysis.
The term calciphylaxis is based on the original descrip- tal design and histology bear little resemblance to the
human situation. Hence, the variety of nomenclature intion in experimental non-uremic rats, in which animals
were sensitized by various measures and subsequently the literature includes calcifying panniculitis, calcific ure-
mic arteriolopathy, necrotizing panniculitis and calcino-injected with albumin or traumatized [16]. The animals
developed severe calcification at the injection site as well sis cutis. The condition as described in over 98% of all
reported cases is characterized by cutaneous painful ul-as in the atrium of the heart. Calcification was found in
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Table 4. Disease progression and response to treatment high serum phosphate and Ca  P product increased
in 27 patients with calciphylaxis presenting with plaques-only
the risk of calciphylaxis [25].
Death within 12 The diagnosis is made clinically. For example, we have
Outcome months calciphylaxis not yet encountered a patient who we considered to have
Therapy Worse Improved/stable Related Not related the condition who had negative investigations. The bone
Nil scan is almost always positive and in most cases, the ab-
N  11 6 (55%) 5 (45%) 6 (100%) 0 normal uptake is in the clinically obvious areas. Compa-
Steroids
rable to the clinical situation, radiologist experience ofN  14 3 (21%) 11 (79%) 3 (60%) 2 (40%)
Parathyroidectomy the disease increases the sensitivity of the test, especially
N  3 3† 0 0 when the changes are subtle. We have encountered only
a Two of these patients obtained significant improvement over 2–6 months but one patient with clinically obvious disease who had a
then relapsed, and 1 other patient had steroid therapy
negative bone scan (which on a repeat scan 2 monthsb Parathyroidectomy
c One patient had both steroid therapy and parathyroidectomy later, was still negative). The diagnosis in this case was
confirmed by x-ray and biopsy. Of the limited number
of patients who had x-rays (N  7), two were negative
in spite of grossly obvious disease. Overall, therefore,cers, usually with eschar, usually on the legs, occurring
bone scan is the test of choice for calciphylaxis.in dialysis or post-transplantation patients. Marked calci-
With regard to bone scan, it is interesting to note thatfication of blood vessels is often found radiologically.
in two of our worst patients, with florid and widespreadSeveral years ago, we described non-ulcerating plaques
deep ulceration of the lower legs, right down to thein the calves as the major presenting feature in five pa-
muscle (similar to Fig. 1B), there was zero uptake in thetients [6]. Very rare reports of similar plaques had been
legs but strong uptake in the lungs. It seems probabledescribed previously [1, 17, 18]. It is clear from the pres-
that the complete denudation of subcutaneous tissue ridsent study that presentation with non-ulcerating plaques
the limbs of calcium-containing tissue.
is far more common than presenting with ulcers. It is im-
There is seldom a need to perform a biopsy, and in
portant to recognize that these lesions are easily missed our experience, this can be hazardous. In two of our
by the physician, who often makes an alternative diagno- four biopsies, both in non-ulcerating patients, ulceration
sis of cellulitis. After the experience of several cases, developed in the region of the incision, within two to six
however, the diagnosis can be made rapidly. The condi- weeks. The ulceration, surprisingly, did not develop at
tion has now become so prevalent in our peritoneal dial- the exact biopsy site but 2 to 3 cm away. Both patients
ysis population that we often routinely examine for and died of rapidly progressive disease. Others have noted
find the condition at clinic visits in early asymptomatic poor healing post-biopsy [26]. A single biopsy may be
patients. negative in the presence of the disease. In one patient
The apparent increased incidence of this condition three biopsies had to be taken. The first biopsy did not
may, therefore, be partially related to increased physi- contain subcutaneous tissue. The second biopsy was neg-
cian awareness. Others, though, have noted an increase ative for calciphylaxis, in spite of large amounts of subcu-
in incidence of ulcerating calciphylaxis in the past few taneous tissue in the sample. Only the third biopsy con-
years [8, 19, 20]. The basics of dialysis therapy have firmed the diagnosis. We have encountered a similar
changed little over the past two decades, other than patient in another hospital who needed three biopsies
changing clearance targets, but our therapy of renal bone to make the diagnosis. The diagnosis was pursued by
disease has changed dramatically. Hyperphosphatemia repeated biopsies on account of the attending physician
has assumed increasing importance as a direct stimulator being unfamiliar with the condition. Thus, biopsies over-
of PTH production in dialysis patients [20] and has re- all gave no new information to the nephrologist (except
cently been shown to be a predictor of mortality [21]. in the first biopsy, which was on our index case). Because
Calcium salts have replaced aluminum salts as phosphate they can be hazardous, biopsies should be discouraged.
binders and the usage of vitamin D has increased. Our The role of parathyroidectomy in this condition is un-
finding that the use of calcium salts plus vitamin D in- clear and our report does little to expand current knowl-
creases the risk of developing calciphylaxis suggests that edge in this area. Some dramatic results have been re-
the disease may be preventable by using non-calcium ported [15] but there is clearly a publication bias for
containing phosphate binders, or even calcimimetics [22]. positive reports. In a review of 47 patients, outcome
Interestingly, it has recently been shown that coronary was unchanged following parathyroidectomy [14]. How-
artery calcification increases in young dialysis patients ever, all patients in these studies have had ulcerating
related to calcium-salt ingestion [23], but this does not disease. In our case control study, all three patients had
progress when changed to non-calcium phosphate bind- resolution of subcutaneous plaques, although in one of
these patients, concurrent steroids were given. In our in-ers [24]. Our results confirm a very recent report in which
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Table 5. Case control study of 24 patients with calciphylaxis presenting as plaques-only with two controls per patient
Univariate Multivariate
Cases Control OR  95% CI P OR  95% CI P
Phosphate mmol/L 2.15  0.79 1.8  0.53 2.40 (1.009–5.714) 0.048 2.6 (1.05–6.45) 0.038
Ca mmol/L 2.39  0.25 2.34  0.23 2.51 (0.042–3.74) 0.42 2.62 (0.3–21.7) 0.37
Ca  P mmol/L 5.23  1.8 4.26  1.48 1.43 (1.013–2.02) 0.042 1.46 (1.02–20.9) 0.038
PTH ng/L 527  323 585  670 1.0 (0.999–1.001) 0.68 1.0 (0.99–1.01) 0.79
CaCO3
3 & 4 months 4.0 (1.07–14.92) 0.039 3.92 (0.98–15.6) 0.053
Vitamin D
3 & 4 months 2.6 (0.818–8.26) 0.55 2.51 (0.78–8.06) 0.62
Ca  Vitamin D
3 & 4 months 3.25 (1.009–10.529) 0.048 4.05 (1.14–14.5) 0.03
Ca  Vitamin D
1 month 2.86 (0.96–8.6) 0.060 3.56 (1.0–12.66) 0.05
Data on 3 patients were incomplete and are not included in the case control study.
dex case, the very extensive and confluent plaques ex- ever, these conditions are not prerequisite for the condi-
tion, as our three most severe cases had no known detect-tending throughout the entire calves (similar to Fig. 1A)
started to resolve within two weeks of parathyroidec- able vascular disease.
The female predisposition to calciphylaxis may be par-tomy and within four months had completely resolved.
We have not considered parathyroidectomy on exten- tially related to the increased fat mass in females because
fat has less blood supply than other tissues. The increasedsively ulcerated patients because they are so often debili-
tated, have advanced disease and are in too poor a condi- frequency of diabetes in these patients could further
compromise circulation. It is possible that the increasedtion for surgery. Further studies are needed to define
the role of parathyroidectomy. frequency of calciphylaxis in PD patients is due to the
constant exposure to hyperphosphatemia compared toThe dramatic twofold increase in mortality when ul-
cers develop strongly suggests that all possible therapy hemodialysis, where significant reductions in serum phos-
phate occur after each treatment.should be entertained to prevent ulceration. The decision
to treat some patients with steroids was initially prompted Another factor could be that adynamic bone disease
is more common in peritoneal dialysis patients and inby a predominance of cellulitis-type symptoms and signs
in several patients. In several patients, the response to diabetics [31, 32]. In this condition, the bones have a
reduced buffering capacity for additional calcium, pre-treatment was dramatic, with reduction in pain and red-
ness within 3 to 10 days. In many others, the disappear- sumably leading to increased tendency for tissue calcifi-
cation [33]. Parathyroidectomy in such patients with cal-ance of the lesions takes two to three months after ther-
apy started. The majority of plaque-only patients develop ciphylaxis is unlikely to be of any benefit. Although our
results confirm previous reports of the lack of effect ofulceration (with an 89% mortality rate) when untreated
as distinct from only 21% of those treated with steroids. PTH levels on onset of calciphylaxis [11, 25] this cannot
be ruled out as a factor due to the recent finding that theHowever, the low numbers of patients and the arbitrary
decision-making for steroid therapy do not allow valid 1-84 intact hormone assay may include a very significant
amount of inactive 7-84 PTH [34]. Further studies ofstatistical analysis. Only two patients in the literature
have been given steroids [27, 28], with one patient ob- active PTH levels in calciphylaxis need to be performed.
We are convinced that plaque-only patients have cal-taining a good response was obtained [27] but not the
other. It is our recommendation that all patients with ciphylaxis rather than a novel calcifying disorder for the
following reasons. The histology and bone scans are thenon-ulcerating disease be given a therapeutic trial of
steroids, unless medical contraindications exist, but fur- same whether ulcerating or not. One third of patients
with plaques-only develop ulceration and many patientsther studies are clearly needed.
Hyperbaric oxygen has been shown to reverse ulcer- have both ulcers and plaques simultaneously. Plaque-
only presentation probably reflects early, potentiallyation in some patients [29] and in support of this therapy,
low skin oxygen tensions have been found in the limbs treatable disease.
In conclusion, the frequency of calciphylaxis seems toof patients with calciphylaxis [30]. We have no experi-
ence of its usefulness. be markedly increasing, probably related to long-term
and wide usage of calcium salts plus vitamin D. The dis-Part of the high mortality rate in these patients relates
to the accompanying co-morbid conditions that include ease is clinically obvious but can be confirmed by bone
scan. The vast majority of cases have non-ulceratingcardiovascular disease, poor nutrition and diabetes. How-
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